Susceptible adults (n Å 105) were enrolled into a randomized double-blind study of rimantadine treatment of experimental influenza A infection. Subjects were cloistered for 8 days and challenged with a rimantadine-sensitive strain of influenza A H1N1 virus at the end of the first day. Fortyeight hours after challenge and for 8 days, 54 subjects received placebo and 51 received rimantadine (100 mg orally, twice a day). Symptoms, signs, and pathophysiologies were monitored. Nine subjects were not infected. Seventeen subjects (38%) in the rimantadine and 26 (53%) in the placebo group became ill. A beneficial effect of rimantadine was documented for virus shedding, symptom load, and sinus pain. Rimantadine had no effect on nasal patency, mucociliary clearance, nasal signs, or on symptoms and signs of otologic complications. These results do not support a preventive effect of rimantadine on the development of otologic manifestations of influenza A infection in adults.
Otitis media (OM) is characterized by the presence of in-
Experimental respiratory virus infection of human adults has been used to study the pathogenesis of the virus infection and flammation within the middle ear and is second in frequency of diseases affecting infants and children only to upper respiraits complications. In two studies, experimental influenza A virus infection caused sequential otologic complications, intory tract infections (URIs) [1] . Established OM is refractory to current methods of medical treatment and can persist for cluding eustachian tube dysfunction (80%), middle ear underpressures (70%), and OM (20%) after the initial expression of weeks, months, or even years [2] . Epidemiologic studies show that ú50% of new episodes of OM are temporally associated the signs and symptoms of the primary infection [7, 8] . These observations suggest a causal pathway leading from virus infecwith a viral URI, and experimental studies document a causal relationship between the two diseases [3 -8] . Our understandtion to OM via the intermediate development of eustachian tube dysfunction and middle ear underpressures. This experimental ing of OM pathogenesis predicts a temporal delay between the onset of virus infection, symptom presentation, and OM. In setting may be ideal for evaluating strategies to prevent the otologic complications of a viral URI, since objective markers theory, this delay can be exploited to reduce the risk of otologic complications by treating the primary virus infection. This of otologic involvement are provoked in relatively high number, there appears to be a window for prophylaxis of the complistrategy has advantages over the prolonged use of antivirals for prophylaxis. Since the target population is circumscribed cation by antiviral treatment after symptom presentation, and an approved relatively safe and effective antiviral, rimantadine, to symptomatic ''at risk'' persons, the required duration of therapy can be limited to the expected period of viral shedding, is available for treatment [9 -11] . The aim of the present study was to determine if rimantadine treatment after symptom onset and an antiviral with a reasonable likelihood of efficacy can be selected on the basis of concurrent viral activity within the decreases the frequency and severity of the otologic complications during experimental influenza A virus infection in adults. community or by rapid diagnostic testing. Thus, a significant effect on the incidence and prevalence of OM could be realized by targeted antiviral treatment of seasonally defined URIs.
Materials and Methods
vidual doses with lactose filler were repackaged in gelatin capsules, specific-serum HI antibody between the prechallenge and convalescent samples. Illness was defined as a baseline-adjusted sympand identical-appearing lactose placebos were formulated at the Children's Hospital of Pittsburgh. Randomization codes were gentom score of §4 on 2 consecutive days. Data collected on study day 0 were considered to be representaerated and maintained under seal until completion of the study. Study medication was supplied in numerically coded containers tive of the baseline state, and the values for all continuous variables on study days 1-7 were adjusted by subtracting the corresponding and dispensed under observation as unit doses at the cloister site.
Challenge virus. The challenge virus was a safety-tested, rivalue recorded on study day 0 (baseline-adjusted). For each subject and study day, four influenza-related summary symptom scores mantadine-sensitive clinical isolate of influenza A/Kawasaki/9/86 (H1N1) virus (wild type, lot E-262; NIH) [11] .
were constructed corresponding to nasal symptoms (sum of baseline-adjusted scores for rhinorrhea, nasal congestion, and sneezDesign. The study was a double-blind, placebo-controlled randomized trial of rimantadine treatment of experimental influenza ing), throat symptoms (sum of baseline-adjusted scores for sore throat and cough), systemic symptoms (sum of baseline-adjusted A virus infection. Subjects were randomized by entry number (equal numbers for blocks of 10) to treatment with either placebo scores for malaise, headache, chilliness, muscle ache, joint pain, sweats, and fever), and total symptoms (sum of all scores). or rimantadine and studied in 3 cohorts (n Å 30, 32, and 43) during 1 calendar year. Subjects reported to a local hotel at Ç6:00 P.M.,
For each subject on each day, symptoms suggestive of complications including earache, sinus pain, and chest congestion were a time that was defined as the beginning of study day 0. They were cloistered in individual rooms for 8 days (study days 0-7).
reduced to a dichotomous classification (present or absent). For treatment side effects, the symptom was defined as present or Twenty-four hours after admission, 0.25 mL of virus inoculum per nostril was administered intranasally as coarse drops (total absent for each subject on the basis of a score ú0 on any treatment day. Physician-rated nasal and otologic signs were reduced to a dose, 10 7 TCID 50 ). Forty-eight hours after inoculation, subjects were given under observation their first dose of medication as per dichotomous normal-abnormal classification. Similarly, subjects were classified dichotomously with respect to the presence or abcode (100 mg of rimantadine HCl or placebo as capsules by mouth). Repeat dosing was done at 12-h intervals for a total of 8 sence of OM on the basis of a diagnosis of unilateral or bilateral effusion without respect to accompanying symptoms. For each ear days (5 days of cloister and 3 outpatient days). Subjects were not permitted to take over-the-counter or prescription medications with and study session, middle ear pressure was defined as abnormal if the measured pressure was less than or equal to 0100 mm H 2 O. the exception of birth control pills.
Each day each subject received a general physical examination Eustachian tube function was defined as abnormal if, at a given test session, sonotubometry failed to detect tubal openings (ú10 by a physician, pneumatic otoendoscopic and nasal examinations by an otolaryngologist, and nasal lavage for virus recovery as dB increase in canal sound pressure level) on any of 4 consecutive deglutions. previously described [13] . Symptoms consisting of sneezing, nasal discharge, nasal congestion, earache, sinus pain, sore throat, cough, Statistical methods. In the analysis, the data for the 3 cohorts were combined. The tested hypothesis was that active treatment chest congestion, malaise, headache, chilliness, muscle ache, joint pain, sweats, and fever were rated by the subjects on a four-point, would promote a more rapid resolution of signs, symptoms, and pathophysiologies compared with that of placebo treatment, and 0 to 3 scale, corresponding to none, mild, moderate, or severe. Beginning on study day 3, the subjects completed a second daily therefore one-tailed statistical tests were used. For global tests of patterned responses in continuous variables, we used repeated symptom diary, which listed 15 symptoms reported previously as being possibly or probably related to either amantadine or rimanmeasures analysis of variance (ANOVA) (version 3.1, Stat Soft, Tulsa, OK). A significance level of a £ .10 was considered suffitadine treatment. Also, on each day of cloister, expelled nasal secretion weights were determined, nasal mucociliary clearance cient to allow for secondary testings of the paired data for each day using the Mann-Whitney U or Student's t test as appropriate function was evaluated (1 time), nasal congestion was measured by anterior rhinometry (2 times), and temperatures, middle ear (a £ .05). For global tests of population responses in dichotomous variables, Fisher's exact test was used and evaluated at a £ .05 pressures, and eustachian tube function were measured (3 times) using instruments and methods previously described [7] .
(version 6.0, NCSS, http://www.ncss.com). For repeated measures in dichotomous variables, Fisher's exact test was evaluated at a All subjects developing OM were treated with a 10-day course of an appropriate antibiotic. Collected lavage samples were inocu-£ .03 to compensate for the effect of the multiple comparisons. The convention mean { SE was used throughout. lated immediately into veal infusion broth and frozen at 070ЊC. These were inoculated onto MDCK monolayers in triplicate, and virus was identified by hemadsorption [14] . The first isolate was Results confirmed to be influenza A by immunofluorescence testing. Convalescent blood samples were collected Ç2 weeks after subjects Population. We studied 105 susceptible subjects (1 Hiswere dismissed from cloister and assayed for HI antibody titer by panic, 18 black, and 86 white). Mean age was 31.1 { 10.6 years standard techniques [12] .
(range: 18 -50). There were 50 men. There were 2 dropouts: 1 Study data. Data consisted of the results for viral shedding, subject assigned to the placebo group left cloister and 1 asvital signs, subject-rated symptoms, physician-rated signs, secresigned to the rimantadine group refused treatment after dose tion weights, and tests measuring nasal mucociliary clearance funcone. Of those remaining, 50 received rimantadine treatment tion, nasal patency, eustachian tube function, and middle ear presand 53 were given placebo.
sure. The duration of viral shedding was defined as the number of Side effects of medications. None of the placebo-treated days between the first and last day of virus isolation. Infection was defined as viral shedding on §1 day or a §4-fold rise in subjects reported adverse events. One rimantadine-treated sub-JID 1998;177 (May) ject discontinued the medication after the first dose because of self-reported hallucinations, confusion, and nervousness; a second subject discontinued treatment after the ninth dose because of gastrointestinal complaints. More specific side effects were reported by a greater percentage of subjects receiving the rimantadine treatment than by those given placebo: dry mouth (active, 24%; placebo, 4%), anxiety (active, 14%; placebo, 7%), nervousness (active, 6%; placebo, 2%), shakiness (active, 4%; placebo, 2%), nausea (active, 10%; placebo, 6%), vomiting (active, 4%; placebo, 0%), and hallucinations (active, 2%; placebo, 0%); however, only the between-group difference for dry mouth was significant (P õ .05).
Infection and illness. A total of 35 subjects (70%) in the rimantadine and 42 (79%) in the placebo group shed virus, and 36 (72%) in the rimantadine and 46 (87%) in the placebo group seroconverted. The average days of virus shedding was 1.8 { 1.6 for the rimantadine group and 3.2 { 2.3 for the placebo group overall and 2.6 { 1.3 for the rimantadine-treated and 4.0 { 1.8 for the placebo-treated subgroups who shed virus (P õ .05) Nine subjects were not infected (5, rimantadine; 4, placebo). All comparisons are based on data available for the infected subgroups of the rimantadine-(n, 45) and placebotreated (n Å 49) subjects.
The first observation of shedding occurred before initiation of treatment in all (31, day 1; 4, day 2) of the rimantadinetreated subjects and in 95% (33, day 1; 7, day 2; 2, day 3) of the placebo-treated subjects. The frequencies of viral shedding on each day were 69%, 73%, 33%, 11%, 7%, 4%, and 2% for and 4% for the placebo group. Between-group differences were interval about average values for placebo-treated subjects (छ). Sigstatistically significant on study days 3, 4, 5, and 6 (P õ .03).
nificance levels of treatment effect were determined by analysis of The illness caused by the virus infection was relatively mild.
variance: P Å .05 for total, P Å .06 for systemic and for throat, and Only 3 subjects (5%) in the rimantadine group (before treat-P Å .32 for nasal symptom summary score. ment initiation) and no subject in the placebo group had significant temperature elevations ( §37.8ЊC). A total of 17 subjects (38%) in the rimantadine group and 26 (53%) in the Figure 2 shows the daily percentages of infected subjects in the 2 groups presenting with a total score of §4 and the perplacebo group were judged to be ill (P Å not significant [NS] ). The baseline-adjusted total symptom scores for the follow-up centages of subjects in the 2 groups who reported sinus pain and chest congestion. The frequencies of symptom reporting period varied between 0 and 65; 25% of the subjects had a total score of £6 in the rimantadine group and of £4 in the for these three measures showed a more pronounced decrease after initiation of the rimantadine treatment compared with the placebo group.
Symptoms and signs of influenza illness. Figure 1 shows the placebo treatment. Between-group differences were significant on days 4 and 5 for total symptoms and on day 5 for sinus average baseline-adjusted, nasal, throat, and systemic symptom scores as a function of study day for the rimantadine-and pain (P õ .03). On day 0, the frequency of subjects presenting with abnormal physician-rated signs for nasal patency (active, placebo-treated subjects. In both groups, all three scores peaked on days 2 and 3 and then decreased to approach 0 by day 7.
35%; placebo, 18%), mucosal edema (active, 26%; placebo, 10%), mucosal color (active, 24%; placebo, 10%), and quantity For the 2 pretreatment days, the average values for the rimantadine group were well within the 95% confidence interval of rhinorrhea (active, 33%; placebo, 14%) was greater in the rimantadine group. Those frequencies increased significantly defined for the placebo group, but on the treatment days, those values were at or below the lower bound of the confidence in both groups to peak between days 3 and 5 and then slowly decreased over the follow-up period. Between-group differinterval. These scores were significantly less in the rimantadine group on study days 4 -6 for the total symptom score, on study ences at baseline were retained throughout the study period with no evidence of an effect of the active treatment on any day 5 for the systemic symptom score, and on study days 5 and 6 for the throat symptom score (P õ .05).
of these measures. No subjects had signs of sinus drainage.
brane signs in both groups peaked at Ç50% on day 3 and then decreased. There was no evidence of treatment effect on either of these measures (P Å NS). On each study day, the number of sessions with eustachian tube function failure was summed over the two ears, yielding a maximum value of 6 (2 ears 1 3 sessions/day) for this index of dysfunction. For both groups, the index showed a progressive increase to a maximum on day 3 and then a partial recovery with time. On day 0, the average value of the index was 0.6 { 0.9 for the placebo group and 1.3 { 1.8 for the rimantadine group. The average change from baseline in this index during the treatment period was 1.3 { 1.9 and 1.4 { 2.1 for the rimantadine and placebo groups, respectively (P Å NS). Figure  3 shows the percentage of persons in the 2 groups with at least unilateral abnormal middle ear pressure on each day. For both groups, that frequency increased on study day 2, peaked on study day 4 or 5, and showed little evidence of recovery. At most times, the percentage of persons with abnormal middle ear pressures was greater in the rimantadine group. For ears, the average number of days with abnormal negative middle In both groups, temperature and secretion weights peaked on study day 2 or 3 and then decreased to approach baseline. Average nasal conductance showed a shallow and progressive decrease with time, and average clearance time increased to a plateau maintained over days 4 -7. The significance of the treatment effect calculated by ANOVA was P Å .67 for conductance, P Å .19 for temperature, P Å .35 for clearance, and P Å .12 for secretion weight. The average change from baseline summed over the treatment period was 0.1 { 5.7 and 1.6 { 5.4ЊC for temperature, 1.4 { 10.3 and 6.0 { 17.0 g for secretion weight, 15.3 { 32.0 versus 14.6 { 29.1 min for clearance time, and 00.24 { 0.74 versus 00.30 { 0.65 for conductance in the rimantadine and placebo groups, respectively (P Å NS).
Otologic signs, symptoms, and pathophysiologies. Figure  3 shows data on the temporal expression of otologic symptoms, signs, and pathophysiologies for the 2 groups. A total of 16 subjects (36%) in the rimantadine group and 26 (58%) in the placebo group reported earache on at least 1 day of cloister. Ç10%. The number of persons with abnormal tympanic mem-ear pressures during the treatment period was 1.6 { 1.9 in indicators of otologic complications vis a vis symptom presentation, which had the effect of decreasing the window available those given rimantadine and 1.6 { 1.8 in those given placebo (P Å NS). For persons, the average number of days with abnormal for prophylaxis. This temporal pattern is not consistent with that reported for other studies using this model and, if conmiddle ear pressures during the treatment period was not significantly different in the rimantadine (2.4 { 2.0) and placebo firmed, would undermine the rationale for this intervention strategy [7, 8, 16 ]. (2.0 { 2.0) groups.
During the study, 5 subjects (6%) were diagnosed with These results suggest the hypothesis that the different influenza A -provoked signs, symptoms, and pathophysiologies can OM. Four cases were unilateral with onsets on study days 1 (rimantadine), 3 (rimantadine), 4 (placebo), and 6 (placebo); be assigned to one of two domains on the basis of a positive response to rimantadine treatment. The outcomes positively 1 case was bilateral (rimantadine) with an onset on study day 4 (P Å NS). Tympanocentesis was done on 2 of these ears, affected by rimantadine are associated with measures of viral replication, secretion production, and generalized signs and and the recovered effusions were culture-negative for bacteria and virus.
symptoms. These outcomes are the expressed effects of the primary host response to infection and may be feedback-controlled by the decreased virus load consequent to rimantadine Discussion treatment [17, 18] . In contrast, the domain of responses not affected by rimantadine include nasal congestion, mucociliary These results confirm the previously reported benefit of rimantadine treatment for certain signs and symptoms of influstasis, and eustachian tube obstruction. These responses are provoked by a variety of stimuli that promote nasal inflammaenza A virus infection in adults [9, 10] . Rimantadine given orally at a dose of 100 mg twice daily beginning 48 h after tion and may function to protect the sinuses, lungs, and middle ears [19] . Consequently, they may be feedback-modulated by virus exposure and at the time of peak symptoms shortened the duration of virus shedding and significantly decreased the factors that track the degree of nasal inflammation, residual effects of which can be measured long after suppression of the total symptom load. Also, there were significantly fewer infected subjects who reported sinus pain, and fewer reported inciting stimulus. Unfortunately, the continued persistence of these responses can be pathophysiological and, by failing to chest congestion in the group given rimantadine. No effect of rimantadine treatment was suggested by the objective tests that resolve promptly, can in themselves promote the development of complications. If validated, effective prophylaxis of middle assessed nasal patency and nasal mucociliary clearance function or by the physician-rated signs of nasal inflammation. As ear complications during a viral URI may require both antiviral therapy and adjunctive antiinflammatory therapy. previously reported, rimantadine treatment did not adversely affect the immune response to influenza A virus as evidenced
In the current study, the initiation of treatment was timed to correspond to that of unambiguous symptom presentation, since by the similar frequency of subjects in the 2 groups who developed increased homologous HI serum antibody titers after chalin practice, antiviral treatments would be initiated only after recognition of the presence of a URI by symptoms or signs lenge [15] .
A variety of evidence suggests that the development of OM and subsequent determination of an etiology potentially responsive to the specific antiviral (e.g., seasonal virus epidemic, rapid as a complication of viral URIs is mediated by a virus-induced disruption of normal eustachian tube function, which in turn virus identification test). Also, the choice to explore the efficacy of antiviral treatment as opposed to antiviral prophylaxis was causes middle ear underpressures and OM by hydrops ex vacuo [7, 8] . Thus, treating a URI episode with an effective antiviral made after consideration was given to the overall welfare of the intended target population, children. To have a significant could prevent the development of OM by decreasing the virus load and suppressing or reversing the provoked eustachian tube effect on the incidence of OM, rimantadine prophylaxis would need to be extended to a majority of infants and children at dysfunction and consequent middle ear abnormalities. The results of the present study for otologic symptoms, signs, and risk for influenza A infection. While rare, the side effects of rimantadine would be made more manifest in frequency by pathophysiologies do not support that hypothesis. Specifically, there were no significant or apparent differences among treatthe large number of children targeted for prophylaxis. The probability of realizing these side effects could be lessened by ment groups in the frequency of infected subjects reporting earache, in the physician-rated signs of otologic involvement, decreasing rimantadine use to limited periods of time in children with a high likelihood of concurrent infection. in the frequencies of subjects with either eustachian tube dysfunction or middle ear underpressures, or in the number of However, it is likely that the potency of the antiviral and timing of the intervention are important variables in developing diagnosed OM episodes. Of interest, in the placebo-treatment group, the symptoms and signs of influenza illness were relastrategies to prevent OM secondary to viral URIs. In that regard, newer drugs, such as intranasal zanamivir (GG167), a tively mild compared with those of previous studies, but the frequencies of otologic symptoms and signs, including earache viral neuraminidase inhibitor with significantly lesser side effects than rimantadine, can be considered for extended prophyand abnormal middle ear pressures, were similar across studies [7, 8, 16 ]. Also of note was the early development of these laxis or early treatment of influenza virus infection to prevent
